CA2736922C - Use of an ang-(1-7) receptor agonist in acute lung injury - Google Patents

Use of an ang-(1-7) receptor agonist in acute lung injury Download PDF

Info

Publication number
CA2736922C
CA2736922C CA2736922A CA2736922A CA2736922C CA 2736922 C CA2736922 C CA 2736922C CA 2736922 A CA2736922 A CA 2736922A CA 2736922 A CA2736922 A CA 2736922A CA 2736922 C CA2736922 C CA 2736922C
Authority
CA
Canada
Prior art keywords
receptor agonist
ang
peptidic
seq
lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2736922A
Other languages
English (en)
French (fr)
Other versions
CA2736922A1 (en
Inventor
Thomas Walther
Wolfgang Kuebler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Charite Universitaetsmedizin Berlin
Original Assignee
Charite Universitaetsmedizin Berlin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charite Universitaetsmedizin Berlin filed Critical Charite Universitaetsmedizin Berlin
Publication of CA2736922A1 publication Critical patent/CA2736922A1/en
Application granted granted Critical
Publication of CA2736922C publication Critical patent/CA2736922C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2736922A 2008-09-12 2009-09-11 Use of an ang-(1-7) receptor agonist in acute lung injury Expired - Fee Related CA2736922C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08016142.5 2008-09-12
EP08016142A EP2163259B1 (en) 2008-09-12 2008-09-12 Use of an Ang-(1-7) receptor agonist in acute lung injury
PCT/EP2009/006619 WO2010028845A2 (en) 2008-09-12 2009-09-11 Use of an ang-(1-7) receptor agonist in acute lung injury

Publications (2)

Publication Number Publication Date
CA2736922A1 CA2736922A1 (en) 2010-03-18
CA2736922C true CA2736922C (en) 2014-08-19

Family

ID=40430691

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2736922A Expired - Fee Related CA2736922C (en) 2008-09-12 2009-09-11 Use of an ang-(1-7) receptor agonist in acute lung injury

Country Status (9)

Country Link
US (4) US20110281805A1 (enExample)
EP (2) EP2163259B1 (enExample)
JP (2) JP2012502071A (enExample)
KR (1) KR20110074978A (enExample)
CN (2) CN102164614B (enExample)
BR (2) BR122013002187A2 (enExample)
CA (1) CA2736922C (enExample)
ES (1) ES2393455T3 (enExample)
WO (1) WO2010028845A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2163259B1 (en) * 2008-09-12 2012-06-13 Charité-Universitätsmedizin Berlin (Charité) Use of an Ang-(1-7) receptor agonist in acute lung injury
CN104302305A (zh) * 2011-12-16 2015-01-21 塔瑞克斯制药有限公司 用于治疗纤维化的血管紧张素
CN102532265A (zh) * 2011-12-29 2012-07-04 中国人民解放军第四军医大学 一种短肽、其异构体及其应用
CA2863699A1 (en) * 2012-02-10 2013-08-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of peripheral vascular disease
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
AU2013315004A1 (en) * 2012-09-17 2015-04-02 Tarix Pharmaceuticals Ltd. Oral formulations of angiotensin
US8633158B1 (en) * 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
WO2014189634A1 (en) * 2013-04-19 2014-11-27 University Of Iowa Research Foundation Angiotensins in muscular dystrophy
EP3003345A4 (en) 2013-05-24 2017-03-01 Tarix Pharmaceuticals Ltd. Angiotensin peptides in treating marfan syndrome and related disorders
WO2015054005A1 (en) * 2013-10-11 2015-04-16 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of bdnf-related conditions
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
KR20170026368A (ko) * 2014-07-17 2017-03-08 유니버시티 오브 써던 캘리포니아 근골격 질환들의 치료를 위한 방법들, 화합물들 및 조성물들
US10183055B2 (en) 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
WO2016014342A2 (en) 2014-07-21 2016-01-28 Arizona Board Of Regents For The University Of Arizona Ang-(1-7) derviative oligopeptides and methods for using and producing the same
EP3281133A1 (en) * 2015-04-08 2018-02-14 Koninklijke Philips N.V. Tool for recommendation of ventilation therapy guided by risk score for acute respirator distress syndrome (ards)
WO2018129511A2 (en) * 2017-01-09 2018-07-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) and derivative oligopeptides for the treatment of traumatic brain injury and other cognitive impairments
US20200188473A1 (en) * 2017-05-02 2020-06-18 Beth Israel Deaconess Medical Center, Inc. Combination therapy for cancer
CN112316107B (zh) * 2019-07-17 2023-01-06 首都医科大学附属北京妇产医院 血管紧张素(1-7)在胰腺疾病中的应用
EP4117703A1 (en) * 2020-03-13 2023-01-18 Constant Therapeutics LLC Methods and compositions for treatment of coronavirus infection
WO2022094025A1 (en) * 2020-10-30 2022-05-05 Gere Dizerega Angiotensin-1-7 for the treatment of covid-19
MX2023008832A (es) 2021-01-28 2023-10-23 Capacity Bio Inc Métodos y agentes que estimulan el recambio mitocondrial para el tratamiento de enfermedades.
EP4085921A1 (en) 2021-05-04 2022-11-09 CU-Pharmaceuticals UG Angiotensin-(1-7) in the treatment of sars-cov related diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110895A (en) * 1996-12-16 2000-08-29 University Of Southern California Method of promoting healing in skin grafts
YU78601A (sh) 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
EP1485116A4 (en) * 2002-02-27 2006-06-07 Univ Wake Forest ANGIOTENSIN- (1-7) AND AGONISTS OF ANGIOTENSIN- (1-7) FOR THE INHIBITION OF GROWTH OF CANCER CELLS
US20050119180A1 (en) * 2002-03-28 2005-06-02 Roks Antonius J.M. Use of angiotensin 1-7 for enhancing cardiac function
EP1723962A1 (en) * 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
BRPI0503122A (pt) 2005-05-30 2007-05-02 Univ Minas Gerais composições farmacêuticas do peptìdeo angiotensina-(1-7) [ang-(1-7)] e seus análogos, agonistas e antagonistas usando as ciclodextrinas, seus derivados, e o polìmeros biodegradáveis e/ou dos produtos derivados para uso no controle das funções do sistema reprodutivo
BRPI0502497A (pt) 2005-06-28 2007-02-06 Univ Minas Gerais uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças
BRPI0602366B1 (pt) 2006-04-26 2017-12-12 Universidade Federal De Minas Gerais Use of agonists of the receptor coupled to protein g, but, in the treatment of metabolic syndrome, its components and their complications
WO2008130217A1 (en) * 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
EP2163259B1 (en) * 2008-09-12 2012-06-13 Charité-Universitätsmedizin Berlin (Charité) Use of an Ang-(1-7) receptor agonist in acute lung injury

Also Published As

Publication number Publication date
US20160051621A1 (en) 2016-02-25
US8383772B2 (en) 2013-02-26
WO2010028845A3 (en) 2010-06-10
US20110281805A1 (en) 2011-11-17
JP2012502071A (ja) 2012-01-26
US20120321701A1 (en) 2012-12-20
KR20110074978A (ko) 2011-07-05
EP2163259A1 (en) 2010-03-17
CA2736922A1 (en) 2010-03-18
ES2393455T3 (es) 2012-12-21
JP5881122B2 (ja) 2016-03-09
BRPI0918443A2 (pt) 2015-11-24
US20140073760A1 (en) 2014-03-13
EP2163259B1 (en) 2012-06-13
CN102164614A (zh) 2011-08-24
JP2014074048A (ja) 2014-04-24
BR122013002187A2 (pt) 2016-04-05
WO2010028845A2 (en) 2010-03-18
EP2341938A2 (en) 2011-07-13
CN102164614B (zh) 2014-03-26
HK1161100A1 (en) 2012-08-24
CN103263661A (zh) 2013-08-28

Similar Documents

Publication Publication Date Title
CA2736922C (en) Use of an ang-(1-7) receptor agonist in acute lung injury
Bader ACE2, angiotensin-(1–7), and Mas: the other side of the coin
Santos et al. Pharmacological effects of AVE 0991, a nonpeptide angiotensin‐(1–7) receptor agonist
EP2986308B1 (en) Angiotensin ii in combination for the treatment of hypotension
Juillerat-Jeanneret The other angiotensin II receptor: AT2R as a therapeutic target
Cunha et al. The nonpeptide ANG-(1–7) mimic AVE 0991 attenuates cardiac remodeling and improves baroreflex sensitivity in renovascular hypertensive rats
Ikeda et al. Biased agonism of the angiotensin II type I receptor a potential strategy for the treatment of acute heart failure
Katovich et al. Angiotensin-(1-7) as an antihypertensive, antifibrotic target
TW201735913A (zh) 投與血管加壓劑之方法
CA2613126A1 (en) Use of mas g-protein-coupled receptor agonists and antagonists as apoptotic activity modulators for prevention and treatment of diseases
JP2019501201A (ja) アンジオテンシンｉｉの投与方法
Wen et al. Reduction of infarct size by orally administered des-aspartate-angiotensin I in the ischemic reperfused rat heart
HK1161100B (en) Use of an ang-(1-7) receptor agonist in acute lung injury
JP5477794B2 (ja) エンドキニンｃ／ｄ由来のペプチド
US20140296143A1 (en) Angiotensin-(1-7) As A Chemoprevention Agent
Koch et al. Attenuation of left ventricular dysfunction by an ACE inhibitor after myocardial infarction in a kininogen-deficient rat model.
Yokota et al. Cardioprotective effects of an angiotensin-converting-enzyme inhibitor, imidapril, and Ca2+ channel antagonist, amlodipine, in spontaneously hypertensive rats at established stage of hypertension
Butler et al. Effects of ANG II and III and angiotensin receptor blockers on nasal salt gland secretion and arterial blood pressure in conscious Pekin ducks (Anas platyrhynchos)
HK40050536A (en) Angiotensin ii alone or in combination for the treatment of hypotension
US20150105329A1 (en) Methods and Pharmaceutical Compositions for Prevention or Treatment of Ischemia Related Organ Damage
WO2015155323A1 (en) Br2 antagonist for use in the prevention of the hypotensive effect of patient treated with angiotensin-converting enzyme inhibitors (acei)
Ferrario Corcoran Lecture
HK1229245A1 (en) Angiotensin ii alone or in combination for the treatment of hypotension

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180911